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Reducing maternal deaths from hypertensive disorders:
learning from confidential inquiries
Lucy Chappell and colleagues examine the dramatic reduction in maternal deaths from hypertensive
disorders of pregnancy in the UK and discuss how systematic confidential inquiries may have
contributed
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Key messages
Confidential inquiries into maternal deaths in the UK were established in
1952 and have aimed to report on every pregnancy related death since
then
Maternal deaths from hypertensive disorders of pregnancy have reduced
dramatically in the UK over the past 60 years
Incremental improvement in clinical management and organisation of care
through recommendations made in the confidential inquiry reports and
publication of national guidelines are likely to have driven much of this
decline in recent decades
To tackle global maternal mortality related to hypertensive disorders,
setting up a confidential inquiry is an important first step for many countries
Almost complete eradication of maternal mortality related to hypertensive
disorders of pregnancy seems possible
Maternal deaths in the United Kingdom have been the subject
of confidential inquiries since 1952. In this time, deaths from
hypertensive disorders of pregnancy have substantially reduced
in both absolute and relative terms, from 200 women in a three
year period in England and Wales (1952-54), to three women
across the whole of the UK in the most recent report (2013-15).1
Deaths from hypertensive disorders are also falling globally,
but not as dramatically as in the UK.2 Pre-eclampsia and
eclampsia are still estimated to cause approximately 30 000
maternal deaths annually worldwide, mostly in low and middle
income countries.3 4 As with any death, maternal deaths have a
huge impact on families, particularly as they are usually
unexpected in young adults and involve a child (box 1).
Box 1: Experiencing pre-eclampsia
“Losing anyone is hard at any time but losing your partner when you are on
the cusp of becoming a family is the most devastating thing that can happen
to a dad. From planning on being a family to being alone tears you up; it
happened so suddenly, I went from joy and excitement to devastation just
hours later. This changed the path of my life forever and the lack of care for
grieving partners is abysmal”—man who lost his partner and daughter in 2016
“When you have an arm or leg amputated you can get a prosthetic limb, when
your sweetheart is taken from you there is no prosthetic for an amputated
soul. I tell my son the brightest twinkling star is his mum opening a curtain in
heaven and checking up on us, and his freckles are angel kisses from when
his Mum visits him when he’s fast asleep. There will never be a Champagne
moment in this process, no one can give me back my wife”—man who lost
his wife in 2006
For women sharing their experiences of pre-eclampsia, see http://healthtalk.
org/pre-eclampsia
Over the past 65 years, UK confidential inquiries have assessed
the causes of maternal deaths, searched for avoidable factors,
and aimed to reduce maternal morbidity and mortality by
providing recommendations for clinical care, service
organisation, and research priorities. Identifying the factors
involved in the fall in maternal deaths from hypertensive
disorders in the UK may help other health systems to reduce
their maternal death rates.
We reviewed and analysed the original confidential inquiry
reports, providing aggregated triennial data, from the earliest
(England and Wales, 1952-54) to the latest (UK, 2013-15).
Definitions of maternal deaths and hypertensive disorders used
in these reports are listed in supplementary table 1.
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The changing picture of maternal deaths
from hypertensive disorders
Since the first confidential inquiry into maternal deaths the
number of maternities has fluctuated but, on the whole, remained
stable over time (fig 1), allowing for the change in data
collection from England and Wales to the whole of the UK. By
contrast, the maternal death rate from hypertensive disorders of
pregnancy has shown a strong downward trend, from 9.74
maternal deaths per 100 000 maternities in the first confidential
enquiry (1952-54), to 0.09 per 100 000 in the 2012-14 report.
This trend is most dramatic in recent years and in the first 15
years of the inquiries and has been sustained despite a broadly
similar denominator throughout.
Deaths from hypertensive disorders accounted for a fairly stable
proportion (11-20.5%) of direct maternal deaths (deaths resulting
from obstetric complications of the pregnant state) until 2012-14,
when they fell to only 4.5% of direct deaths (fig 2) and 1.5%
of all maternal deaths (direct and indirect causes).
These figures can be broken down to examine the cause of death
in detail—cerebral, hepatic, miscellaneous, pulmonary, or
renal)—which were first included in the report from 1958-60
(fig 3) (supplementary table 2A and 2B). Before this, deaths
related to hypertensive disorders were ascribed to pre-eclampsia
(21.8%) or eclampsia (24.7%) only, reflecting less detailed
information available to the inquiry.
Over the 65 years of inquiries, intracranial haemorrhage was
the single most common specified cause of death, responsible
for 226 of 1063 maternal hypertensive deaths (21.7%). Other
common causes of death include renal failure, particularly in
earlier reports (6.4%); hepatic causes, including hepatic failure
or necrosis (5.6%); and pulmonary complications, including
acute respiratory distress syndrome (3.5%) and pulmonary
oedema (1.1%), which was last reported in 1994-96. Cardiac
failure and anaesthetic complications were responsible for 1.4%
and 1.2% of deaths over the 65 year period, but no deaths have
been reported since the 1980s.
What has driven the reduction in deaths?
The confidential inquiry reports identify areas for improvement
and make recommendations for clinical care of women with
hypertensive disorders of pregnancy (supplementary table 3).
The rate of decline in mortality from hypertensive disorders
was most rapid between the 1950s and 1970s. Although we
cannot draw causal inferences from the trends noted in this
analysis, it is possible—and has been suggested elsewhere5—that
this rapid rate of decline was due to wider provision and
improved quality of antenatal care with the founding of the NHS
in 1948, leading to earlier detection of hypertension and
appropriate referral to hospital care. Poor antenatal care was
mentioned in early confidential reports as the most frequent
avoidable factor in maternal deaths. Other findings were poor
education provisions for pregnant women and challenges in
organisation of care, particularly difficulties in communication
between community and hospital (supplementary table 3)
(supplementary table 4).
Nutrition also improved in the post-war period, with introduction
of the national milk and vitamin schemes for pregnant women
in the 1940s.6 Improved consumption of calcium in populations
where calcium intake is low has been shown to reduce the
incidence of hypertension in pregnancy,7 although lack of
reliable trend data on the incidence of pregnancy hypertensive
disorders in the UK precludes further analysis. Other
sociological factors may also have contributed to the trend,
particularly improved access to all kinds of healthcare after the
introduction of the NHS and an increase in babies being
delivered in hospital (rather than at home), from 63.7% in 1954
to 91.4% in 1972.8
The decline in maternal mortality between the 1970s and the
millennium is likely to have been achieved by improvements
in organisation of care and clinical management of hypertensive
disorders of pregnancy. Important inquiry recommendations
from this period included senior staff involvement
(supplementary table 4), prompt treatment of systolic
hypertension, raising awareness of fluid overload and the need
for strict fluid balance, and implementation of evidence showing
superiority of magnesium sulfate in eclampsia management
(supplementary table 5).
Cerebral haemorrhage was reported as the most common cause
of death for the first time in the mid-1970s, with
recommendations made to control blood pressure soon thereafter
(supplementary table 3; supplementary table 5). The 1985-87
inquiry reported a death from acute respiratory distress syndrome
for the first time and noted the dangers of fluid overload, with
deaths from pulmonary oedema. It also criticised the use of
diazepam for prevention of eclamptic seizures and advised the
scientific re-evaluation of magnesium sulfate and phenytoin for
the management of eclampsia. The recommendation to have
clear protocols for hypertensive disorders of pregnancy was
first made in the 1988-90 report. After the Eclampsia
Collaborative Trial was published,9 magnesium sulfate for
eclampsia management was recommended in the 1991-93 report
(published in 1996), alongside strict fluid balance in women
with pre-eclampsia and eclampsia. Notably, the last recorded
death from pulmonary oedema associated with hypertensive
disorders of pregnancy in the UK was in 1994-96.
In 1985-87 the main factors requiring improvement were human
factors, with inappropriate delegation of care to junior staff and
communication delays being key concerns. Recommendations
for early involvement of senior staff and the development of
expert regional teams to provide support to non-specialist units
were made (supplementary table 4).
By the millennium, maternal deaths from hypertensive disorders
had substantially reduced, having been less than 1 death per 100
000 maternities for almost a decade. Renal, hepatic, and
pulmonary causes of death had all decreased, leaving cerebral
causes of death, primarily due to intracranial haemorrhage,
remaining. This led to a primary focus on the need to treat
hypertension effectively, the key message from the 2000-02
report onwards (supplementary table 3 fig 4; supplementary
table 5)
The 2003-05 report recommended a treatment threshold of 160
mm Hg systolic blood pressure for starting antihypertensives,
which was subsequently reduced to 150 mm Hg (2006-08). The
latter report also noted that the incidence of eclampsia had
halved, probably due to widespread use of magnesium sulfate.
Recommendations of the confidential inquiries have been
incorporated into specific evidence based guidelines, such as
the first version of the National Institute for Health and Care
Excellence (NICE) Guideline for management of hypertension
in pregnancy published in 2010.10 This guideline advised
screening and prevention of pre-eclampsia with aspirin, lowering
of blood pressure targets, and planned delivery at 37 weeks’
gestation for women with pre-eclampsia. These national
guidelines have promoted universal provision of standardised
care, rather than management by individual clinician preference,
and are likely to have driven the notable recent reduction in
deaths. Alongside this, direct involvement of patient support
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groups in the production of lay summaries of the confidential
inquiry reports has empowered women to seek this standardised
high quality care.
Intracranial haemorrhage remains the most common specific
cause of death from hypertensive disorders of pregnancy overall.
Inadequately treated hypertension is likely to be the most
important aetiological factor in intracranial haemorrhage, so the
monitoring and control of blood pressure through use of clear
blood pressure targets for hypertensive pregnant women is likely
to remain of pivotal importance.
Comparison with other countries
The UK confidential inquiries show the powerful process of
data collation generating research questions guided by clinical
need, these research findings being translated into evidence
based national guidelines and reports, and the resultant
engagement of healthcare workers and influence on clinical
practice leading to improved outcomes. This model is
particularly relevant to outcomes such as maternal deaths, which
are less common in high income settings and are otherwise
difficult to study.
Since their inception in the UK, confidential enquiries into
maternal deaths have been set up in numerous other countries.
The South African inquiries, running since 1997, show that
maternal deaths from hypertensive disorders have decreased
overall between 2002-04 and 2011-13, but remain one of the
top five causes of maternal deaths, responsible for 14.8% of
deaths in 2011-13.11 Similar to the UK, cerebral complications
are the most common cause of death (58.2%), related to failure
to control severe hypertension. The latest report recommends
aggressive control of hypertension, reinforcing the South African
Maternity Guidelines, which implies that guideline
implementation is an important focus in the South African
setting. Teenagers and women under 25 who are pregnant for
the first time are also at higher risk of death from pre-eclampsia,
so reproductive services are being targeted at this group.11
In a recent review of maternal deaths in Norway from 1996 to
2014, hypertensive disorders were the most frequent cause of
maternal deaths, and in 14 of 16 cases assessors concluded that
better care may have improved the outcome.12 Pulmonary
oedema was the most common cause of death (43.8%), followed
by intracranial haemorrhage (37.5%). The authors point to the
lack of recommendations on timing of delivery in women with
hypertensive disorders and treatment thresholds for diastolic
(rather than systolic) blood pressure in the Norwegian obstetric
guidelines at the time of the study. They recommend
implementation of evidence based guidelines (similar to those
implemented in the UK in 2010) with clear systolic treatment
thresholds for hypertension drugs and guidance on fluid
management and timing of delivery.12
France, which has had confidential inquiries since 1996, has
also achieved a substantial reduction in maternal deaths from
hypertensive disorders—the rate halved from 1 per 100 000 live
births in 2007-09 to 0.5 per 100 000 live births in 2010-12.13
The report concludes, however, that scope for improvement
remains, estimating that 70% of these deaths could have been
avoided with better care.
Implications for clinicians and policy
makers
The Global Burden of Disease study of maternal deaths
worldwide reported 29 275 maternal deaths from hypertensive
disorders (95% uncertainty interval, 25 664 to 33 376) in 2013,
42% (12 232) of which were in sub-Saharan Africa and 36%
(10 656) in South Asia.2 In these countries with the highest
burdens and no confidential inquiry processes, there is a strong
case to start inquiries to enable understanding of the specific
factors implicated in maternal deaths in each setting and to make
targeted recommendations. Importantly, although there may be
many similarities and transferable lessons between countries,
other factors may differ across healthcare systems,
demographics, and income settings, highlighting the context
specific nature of each inquiry process. For clinicians and policy
makers considering setting up this process, good case
ascertainment is a key early priority for meaningful confidential
inquiries, and this may have a long latency period as a system
becomes accepted and widespread among clinicians, managers,
and administrative staff. In the UK it took 30 years for the
inquiries to report the same number of maternal deaths as those
reported to the registrar general. In this early phase, rapidly
improving case ascertainment can initially increase apparent
death rates, which may have contributed to the rise in death
rates in the first decade of the South African confidential
inquiries alongside the HIV epidemic, which contributed to
increased maternal deaths at the same time.14
Where inquiries are already established, an in-depth and
integrated review of deaths, healthcare systems, and social
context is necessary for pertinent lessons to be learnt and
recommendations disseminated. Development and
implementation of national, evidence based guidance with
specific recommendations pertinent to all settings on aspirin
prophylaxis, antihypertensive treatment thresholds, fluid
management, and timing of delivery may be a key tool in
successfully lowering maternal deaths from hypertensive
disorders. But further research into the findings and
recommendations of confidential inquiries in other healthcare
settings should be undertaken to investigate which
recommendations and strategies have been able to reduce deaths
most successfully in contexts other than the UK.
In countries where maternal deaths from hypertensive disorders
have become a very rare event, confidential inquiries have found
that, in the majority of these cases, care could still be improved,
and better care may have altered outcome. These findings,
together with recent UK mortality statistics, indicate that almost
complete eradication of maternal mortality from hypertensive
disorders is possible. In countries where maternal mortality is
low, inquiries should broaden to include associated maternal
morbidity and consideration of the impact of management on
perinatal mortality and other adverse fetal outcomes. Reducing
the short and long term maternal and fetal complications of
hypertensive disorders of pregnancy, as well as aiming for
complete eradication of maternal mortality, should be the next
goal.
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pre-eclampsia. Patient group representatives are involved in the Confidential
Enquiries into Maternal Death and provide input to design, management, and
outputs of the programme.
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Figures
Fig 1 Rates of maternal deaths from hypertensive disorders and maternities over time in the UK
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Fig 2 Percentage of direct maternal deaths due to hypertensive disorders over time in the UK
Fig 3 Causes of death from hypertensive disorders in pregnancy by category
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Fig 4 Number of deaths from cerebral and pulmonary causes and timing of recommendations for changes in management
in the UK
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